Onco360 was selected to be a specialty pharmacy network partner for Bayer’s new product NUBEQA® (darolutamide), indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.
“Onco360 is honored to be selected as a specialty pharmacy provider for NUBEQA patients,” said Paul Jardina, President and CEO, Onco360. “The recent approval of NUBEQA provides another treatment option for patients with non-metastatic castration-resistant prostate cancer (nmCRPC). As a provider of this key treatment, Onco360 will utilize its expertise in service delivery, clinical, healthcare professional and community engagement, insurance and billing, and ongoing customer service to support the highly specialized needs of CRPC patients and their physicians.”
Other than skin cancer, prostate cancer is the most common cancer among American men, but it can often be treated successfully. The National Cancer Institute estimates that for 2019 about 174,650 new cases of prostate cancer will occur. Prostate cancer results from the abnormal proliferation of cells within the prostate gland, which is part of a man’s reproductive system. It mainly affects men over the age of 50, and the risk increases with age. Treatment options range from surgery to radiation treatment to therapy using hormone-receptor antagonists (i.e., substances that stop the formation of testosterone or prevent its effect at the target location.) However, in nearly all cases, the cancer eventually becomes resistant to conventional hormone therapy.
CRPC is an advanced form of the disease, where the cancer keeps progressing even when the amount of testosterone is reduced to very low levels in the body. The field of treatment options for castration-resistant patients is rapidly evolving. However, until two years ago, there have been no FDA-approved treatment options for nmCRPC patients with prostate cancer that has not spread to other parts of the body with rising prostate-specific antigen (PSA) levels despite a castrate testosterone level. About one-third of men with nmCRPC go on to develop metastases within two years. In men with progressive nmCRPC, a short PSA doubling time is correlated with shortened time to fist metastasis and death.
Manufactured by Bayer, NUBEQA was approved by the U.S. Food and Drug Administration (FDA) on July 30, 2019, based on the Phase III ARAMIS trial evaluating NUBEQA plus androgen deprivation therapy (ADT), which demonstrated a highly significant improvement in the primary efficacy endpoint of metastasis-free survival (MFS), with a median of 40.4 months designation, which is reserved for medicines that may provide significant improvements in the safety or effectiveness of the treatment of severe conditions. For full Prescribing Information, visit www.nubeqa-us.com.
For more information, please call Onco360 at 1.877.662.6633 or visit us online to refer your patients to Onco360